EE500 Cost-Effectiveness Analysis of Cemiplimab As Second-Line Therapy for Recurrent Cervical Cancer in Japan

Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.2479
https://www.valueinhealthjournal.com/article/S1098-3015(23)02669-4/fulltext
Title : EE500 Cost-Effectiveness Analysis of Cemiplimab As Second-Line Therapy for Recurrent Cervical Cancer in Japan
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)02669-4&doi=10.1016/j.jval.2023.03.2479
First page :
Section Title :
Open access? : No
Section Order : 10269
Categories :
Tags :
Regions :
ViH Article Tags :